Implications of hepatitis B virus genomic variations on treatment outcomes
Journal
Current Pharmacogenomics and Personalized Medicine
Journal Volume
8
Journal Issue
4
Pages
280-288
Date Issued
2010
Author(s)
Abstract
Infection due to hepatitis B virus (HBV) is a global public health issue. With effective treatment, it is possible to prevent disease progression to cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients. Several viral factors have been documented to be associated with disease progression and treatment response, including HBV genotype and several naturally occurring HBV mutants, such as precore stop codon mutation (G1896A) and basal core promoter mutation (A1762T/G1764A). Recent studies suggested that responses to standard interferon or peginterferon are more favourable in patients infected with the HBV virus of genotype A or B than the genotype C or D infection. In contrast, therapeutic responses to nucleos(t)ide analogues are generally comparable between HBV genotypes. In addition to the viral genotype, BCP mutation (A1762T/G1764A) is likely to be associated with a higher sustained viral response in HBeAg-positive patients receiving interferon or peginterferon treatment. In conclusion, therapeutic differences seem to exist among HBV genotypes and genetic variations. However, the definite contribution of each viral factor still remains unclear. Since the majority of current studies included small numbers of patients and were not powered to answer such critical questions, the role of viral genetic variation for treatment outcomes awaits further studies before personalized treatment strategies can be planned. ? 2010 Bentham Science Publishers Ltd.
SDGs
Other Subjects
adefovir dipivoxil; alanine aminotransferase; alpha interferon; alpha2a interferon; alpha2b interferon; entecavir; hepatitis B antigen; interferon; lamivudine; peginterferon; peginterferon alpha2a; peginterferon alpha2b; telbivudine; tenofovir disoproxil; virus DNA; clinical trial (topic); controlled clinical trial (topic); disease course; DNA hybridization; enzyme blood level; gene mutation; genetic association; genetic variability; genotype; hepatitis B; Hepatitis B virus; hepatitis C; human; liver cell carcinoma; liver cirrhosis; meta analysis (topic); molecular cloning; nonhuman; nonsense mutation; promoter region; protein expression; randomized controlled trial (topic); real time polymerase chain reaction; review; seroconversion; single nucleotide polymorphism; stop codon; treatment outcome; virus genome; virus load; virus mutant; virus strain
Type
review